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Abstract
Enhanced external counterpulsation (EECP) is a noninvasive treatment mo-
dality which can increase arterial blood flow in peripheral and coronary arteri-
al disease. Several studies have demonstrated an increase in the flow of the
internal iliacal artery and in carotid and renal perfusion during EECP treat-
ment. We investigated the effect of EECP in patients with erectile dysfunction
(ED). Thirteen patients were treated with EECP for 20 days, 1 h per day.
Patients reported a significant improvement of penile rigidity after comple-
tion of the EECP treatment and a significant improvement of penile peak
systolic flow was measured by Doppler sonography. No adverse effects were
observed. In conclusion, EECP seems to be an effective treatment modality in
patients with ED.
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Introduction
Enhanced external counterpulsation with sequential
pneumatic cuff inflation was introduced in 1983 by
Zheng et al. [1]. EECP causes increase of diastolic pres-
sure that leads to increased coronary perfusion pressure
and enhanced coronary blood flow. The ratio of mean dia-
stolic to mean systolic pressure is increased as well, there-
by modifying the pulse pressure distribution in the aorta
and increasing mean arterial pressure [2]. The result is an
increased peripheral blood flow. Since the introduction of
this treatment, several studies have shown the benefit of
EECP in patients with coronary heart disease [3] or inter-
nal ear disorders [4]. Fricchione et al. [5] reported 12
patients with coronary heart disease who showed a signifi-
cant improvement in myocardial ischemia following
EECP. 33% of these patients also reported an improved
erectile activity. In 1997, the Multicenter Study of
Enhanced External Counterpulsation (MUST-EECP)
showed a decrease of episodes of angina pectoris by 39%
and of nitroglycerin use by 54% after EECP treatment [6].
It was also shown that EECP was able to increase renal
perfusion by 20%, coronary artery perfusion by 20–40%
[7–9], and the urinary output by 60.3% in healthy volun-
teers during EECP treatment [10]. However, flow volume
in the internal iliac artery is increased by 140% during
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EECP [11]. Offergeld et al. [4] could demonstrate a bene-
fit of EECP treatment in patients with internal ear disor-
ders.
The aim of this study was to investigate whether EECP
treatment can improve symptoms in patients with erectile
dysfunction.
Materials and Methods
Between October 1995 and December 1997, 20 patients with
erectile dysfunction were enrolled in a clinical study to evaluate the
EECP treatment. All patients underwent Doppler echocardiography
and duplex scan in order to exclude aortic regurgitation, deep vein
thrombosis and aortic aneurysm. Thus, 7 patients had to be ex-
cluded. The remaining 13 patients were between 43 and 68 years old
(mean 57.85 B 6.32). All 13 patients had a stable life style and a
stable sexual relationship. Six patients were diabetics on oral antidia-
betic drugs, 12 patients were cigarette smokers and 4 patients had a
beginning peripheral artery disease. Clinical evaluation included sex-
ual history and serum hormone levels (LH, FSH, prolactin, testoster-
one and free testosterone). No patient had received hormonal or
yohimbine therapy within 5 months before entering the study, and
all patients had a normal hormonal status. The classification of the
patients was performed as follows: E0 = no erection; E1 = poor erec-
tion, immediate loss; E2 = soft erection, but adequate for coitus; E3 =
full erection.
Before treatment, patients had to answer a questionnaire. In all
patients, intracavernous pharmacotests with rising doses (5–10–15–
20 Ìg) of PGE were performed several times until full erection was
achieved (final PGE dose). The quality of erection was observed after
the application of 5 Ìg PGE. Three and 5 min after application of the
final PGE dose, a duplex sonography of the cavernous body arteries
was performed and the values for resistance index (RI) and peak sys-
tolic blood flow (PS) were measured.
For the EECP treatment the counterpulsation system of Vasome-
dical Inc. (Westbury, USA) was used. EECP works by sequential dia-
stolic inflation and deflation of three pairs of cuffs applied to the
patients calves, lower thighs and upper thighs. Timing of the cuff
compression is triggered by the electrocardiogram. During diastole
the cuffs inflated up to 300 mm Hg starting with the distal pair of
cuffs. During onset of systole, the external pressure is rapidly
released. Thus, by ‘milking’ the blood back to the heart EECP leads to
an increased diastolic aortic pressure and increased flow in the inter-
nal iliac arteries. The administered EECP treatment regimen was 1 h
daily for 5 days a week over 4 weeks.
Within 1 week after completion of the last EECP session, a
reevaluation of the patients (determination of the quality of erection,
duplex sonography after intracavernosal PGE application) was per-
formed. One month after completion of the EECP treatment the
patients were asked to answer the questionnaire for a second time.
In 4 patients a blood sample of the cavernous body was taken
before and after the EECP treatment. After centrifugation serum was
obtained and stored at –175 °C until assayed. The concentration of
vascular endothelial growth factor (VEGF) was determined before
and after EECP with the QuantikineTM human VEGF Immunoassay
(R&D Systems). VEGF is one of the marker proteins of induced
angiogenesis.
Table 1. Quality of erection (E0-3), peak systolic flow (PS) and
resistance index (RI) after pharmacological testing with PGE before
and after EECP: for statistical differences the Wilcoxon test was per-
formed
PS, cm/s
(mean B SD)
RI
(mean B SD)
Quality of erection
(mean B SD)
0.32B0.17 0.58B0.06 1.46B0.67
After EECP 0.60B0.35 0.67B0.07 2.31B0.48
p value 0.017 0.008 0.003
Table 2. The ability of sexual intercourse (SI) before and after
EECP
Age
(years)
Possible SI in % of all attempts
before EECP after EECP
Follow-up
(months)
Duration of
improvement
(months)
0 120 8 2
55 0 0 24 –
54 0 150 17 4
43 0 120 – –
57 !20 150 13 6
64 0 satisfactory SI 9 9
50 !20 150 18 14
63 !20 satisfactory SI 25 12
57 !20 satisfactory SI 10 10
68 !20 150 6 6
59 0 0 2 –
61 0 satisfactory SI 2 2
61 !20 150 2 2
Results
Before EECP treatment, 7 of the 13 patients were com-
pletely unable to have penetrative sexual intercourse (SI),
6 patients only in !20% of all attempts. Ten of the 13
patients reported no spontaneous morning erections with-
in the last year before EECP treatment.
One week after completion of the EECP treatment
there was a significant improvement in peak systolic flow
(p = 0.017), a significant change in the penile resistance
index ( p ! 0.008) and in the quality of erection (p ! 0.003)
after application of 5 Ìg PGE (table 1). Five of the 13
patients reported a considerable subjective improvement
in penile rigidity so that satisfactory SI was now possible,
6 patients reported an improvement of penile rigidity and
satisfactory SI more often than before treatment. In 2
patients penile rigidity remained unchanged (table 2).
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Fig. 1. Serum concentration of VEGF before and after 4 weeks
EECP treatment in 4 patients.
Eight of 10 patients reported that spontaneous morning
erections, previously absent, had returned after EECP.
The mean follow-up time was 11 B 7.35 months. Mean
duration of response (in the 11 responders) was 6.7 B
4.37 months. No side effects of EECP treatment were
reported. The determination of the VEGF concentrations
before and after EECP treatment revealed no significant
(p = 0.072) difference (fig. 1).
Discussion
Erectile dysfunction (ED) is a common health disorder
in elderly men. About 67% of men aged 70 years have
some degree of ED [12]. Although the interest in sexual
activity often remains high in elderly men, less than 5%
receive adequate treatment [12]. One reason for this is
that until Sildenafil no satisfacotry noninvasive treatment
was available. The main treatment alternatives are:
(1) oral drug therapy; (2) vacuum constriction devices;
(3) intracavernous or intraurethral vasoactive drug appli-
cation; (4) penile prosthesis implantation, and (5) venous
and arterial surgery [13]. Until recently, the mainstay of
oral drug therapy was yohimbine, but the outcome data
for this drug therapy do not indicate a significant effect
[14]. Sildenafil, a new therapeutic agent for oral treatment
[15] is a potent inhibitor of cyclic guanosine monophos-
phate in the corpus cavernosum and leads to an increased
penile response to sexual stimulation. In an investigation
by Goldstein et al. [16] 69% of all attempts at sexual inter-
course were successful in the Sildenafil group compared to
22% in the placebo group. The most common adverse
effects were headache, flushing and dyspepsia.
The use of vacuum constriction devices and the penile
application of vasoactive drugs is reliable, however both
are not easy to use, and considerable side effects like pro-
longed erection are possible. In addition, both methods do
not allow spontaneous sexual activity. In an investigation
by Gerber and Levine [17], 51% of the patients who
entered a pharmacological erection program using PGE
discontinued the program due to adverse effects like
penile pain. The risks of penile prosthesis implantation
are infection, erosion, mechanical failure and subsequent
reoperation. The use of venous and arterial surgery is still
investigated. Padma-Nathan et al. [18] investigated the
effectiveness of intraurethral Alprostadil application and
reported a response rate of 64.9% compared to 18.6% for
placebo. The reported adverse effects were penile pain
(32.7%), minor urethral trauma (5.1%) and dizziness
(1.9%). Kim and McVary [19] investigated the effects of
topical PGE application to the penis. They showed a sig-
nificant increase of mean peak systolic flow velocity and 2
of 9 patients had clinical erections after application.
EECP has been shown to improve peripheral blood
flow and could therefore be assumed to improve erectile
function in men with vascular ED as well. In our opinion,
EECP offers a simple and noninvasive treatment for ED
of predominantly vascular origin. Nine of 13 patients
(69%) reported a considerable improvement of the ability
of sexual intercourse after EECP treatment and the mean
duration of response after completion of EECP for these
patients was 7.2 months. With proper patients selection,
side effects have not to be expected. Furthermore, pa-
tients will benefit generally by improved peripheral vas-
cular perfusion of other organs. The significant increase in
peak systolic flow indicates also an improvement in penil
perfusion resulting in an increased resistance index. The
mechanism of the improvement in penile rigidity is un-
clear. One possible explanation is that the increased
arterial perfusion during EECP treatment opens existing
or leads to the development of new collateral channels.
Increase of peak systolic flow after PGE could be a hint
for improved vascular reagibility. However, the EECP
treatment is time consuming and thus costly. The need for
repetitive therapy has also to be taken into account.
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Conclusion
EECP is safe and has been shown to be an effective
treatment modality in patients with ED. However, larger
studies are needed to define subgroups of patients which
benefit the most. EECP seems a promising treatment
alternative especially for patients with generalized periph-
eral vascular disease and erectile dysfunction.
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